{
  "id": 3948,
  "url": "https://nnemf.org/research/3948-preliminary-clinical-comparison-of-hlf-and-elf-regimen",
  "title": "[Preliminary clinical comparison of HLF and ELF regimen in the treatment of advanced gastric carcinoma in middle-aged and elderly patients].",
  "authors": [
    "X Xiong",
    "Z Zhu",
    "Z Wen"
  ],
  "journal": "Zhonghua zhong liu za zhi [Chinese journal of oncology]",
  "year": "2000",
  "doi": null,
  "pmid": "11778280",
  "abstract": "OBJECTIVE: To observe the therapeutic effects and toxicity of HLF (hydroxycamptothecin HCPT/leucovorin LV/fluorouracil 5-Fu) regimen and ELF (etoposide VP-16/LV/5-Fu) regimen in middle-aged and elderly patients with advanced gastric carcinoma. METHODS: A group of twenty-five cases were treated with HLF regimen, and the other group of 23 cases were treated with ELF regimen. RESULTS: Of the 25 cases treated with HLF regimen, there was no complete remission (CR), but there were 12 partial response (PR), 11 no response (NC), and 2 had progressive disease (PD). The response rate (RR) was 48.0%. Of the 23 patients treated with ELF regimen, there was no CR, there were 9 PR, 11 NC, and 3 PD. The RR was 39.1% (P > 0.05). The main toxicity was myelosuppression and stomatocace. Grade III-IV stomatocace in HLF regimen group (68.0%) was more commonly seen than that in ELF regimen group (39.1%, P < 0.05). There was no cardiac or renal toxicity observed. CONCLUSION: HLF regimen is promising for treatment of advanced gastric carcinoma in middle-aged and elderly patients with the merits of low toxicity affecting heart, kidney and bladder except stomatocace, which is worthy of further clinical trial.",
  "effect": "mixed",
  "evidence": "low",
  "extraction": {
    "studyType": "other",
    "studyTypeLabel": "Other",
    "effectDirection": "mixed",
    "evidenceLabel": "Low",
    "population": "Middle-aged and elderly patients with advanced gastric carcinoma",
    "sampleSize": "48",
    "exposure": "ELF <1 MHz",
    "confidencePct": "74",
    "peerReviewed": "yes",
    "mainFindings": "In 25 patients treated with HLF, response rate was 48.0% (0 CR, 12 PR, 11 NC, 2 PD). In 23 patients treated with ELF, response rate was 39.1% (0 CR, 9 PR, 11 NC, 3 PD); the difference was not statistically significant (P > 0.05). Grade III–IV stomatocace was more common with HLF (68.0%) than ELF (39.1%, P < 0.05); no cardiac or renal toxicity was observed.",
    "outcomes": [
      "Tumor response (CR/PR/NC/PD",
      "response rate)",
      "Toxicity (myelosuppression",
      "stomatocace",
      "grade III–IV stomatocace)",
      "Cardiac toxicity",
      "Renal toxicity"
    ],
    "limitations": [
      "No randomization described in abstract",
      "Small sample size (n=48)",
      "No survival outcomes reported (e.g.",
      "overall survival",
      "progression-free survival)",
      "Limited toxicity detail beyond selected adverse events"
    ],
    "keywords": [
      "advanced gastric carcinoma",
      "chemotherapy",
      "hydroxycamptothecin",
      "leucovorin",
      "fluorouracil",
      "etoposide",
      "response rate",
      "toxicity",
      "myelosuppression",
      "stomatocace"
    ],
    "hubs": [],
    "raw": "{\n  \"study_type\": \"other\",\n  \"exposure\": {\n    \"band\": null,\n    \"source\": null,\n    \"frequency_mhz\": null,\n    \"sar_wkg\": null,\n    \"duration\": null\n  },\n  \"population\": \"Middle-aged and elderly patients with advanced gastric carcinoma\",\n  \"sample_size\": 48,\n  \"outcomes\": [\n    \"Tumor response (CR/PR/NC/PD; response rate)\",\n    \"Toxicity (myelosuppression, stomatocace; grade III–IV stomatocace)\",\n    \"Cardiac toxicity\",\n    \"Renal toxicity\"\n  ],\n  \"main_findings\": \"In 25 patients treated with HLF, response rate was 48.0% (0 CR, 12 PR, 11 NC, 2 PD). In 23 patients treated with ELF, response rate was 39.1% (0 CR, 9 PR, 11 NC, 3 PD); the difference was not statistically significant (P > 0.05). Grade III–IV stomatocace was more common with HLF (68.0%) than ELF (39.1%, P < 0.05); no cardiac or renal toxicity was observed.\",\n  \"effect_direction\": \"mixed\",\n  \"limitations\": [\n    \"No randomization described in abstract\",\n    \"Small sample size (n=48)\",\n    \"No survival outcomes reported (e.g., overall survival, progression-free survival)\",\n    \"Limited toxicity detail beyond selected adverse events\"\n  ],\n  \"evidence_strength\": \"low\",\n  \"confidence\": 0.74,\n  \"peer_reviewed_likely\": \"yes\",\n  \"keywords\": [\n    \"advanced gastric carcinoma\",\n    \"chemotherapy\",\n    \"hydroxycamptothecin\",\n    \"leucovorin\",\n    \"fluorouracil\",\n    \"etoposide\",\n    \"response rate\",\n    \"toxicity\",\n    \"myelosuppression\",\n    \"stomatocace\"\n  ],\n  \"suggested_hubs\": []\n}"
  },
  "synthesis": null,
  "synthesisStatus": "pending",
  "originalHref": "https://pubmed.ncbi.nlm.nih.gov/11778280/",
  "sourceUrl": "https://rfsafe.org/mel/paper.php?id=3948",
  "updated": "2026-02-13 07:44:36"
}